-
ctDNA-Guided Adaptive De-escalation Therapy for Advanced NSCLC: Ready for Prime Time?
Add ILCN as a preferred sourceIn a recent commentary, Drs. Roberto Borea and Christian Rolfo analyze the findings from a nonrandomized controlled trial and address the feasibility of ctDNA-guided targeted therapy in patients with advanced non-small cell lung cancer.
More Recent News
-
From Access to Eligibility: What Poland’s Real-World Stage III NSCLC Data Reveal About Treatment Pathways and Health Policy
Dr. Łukasz Kuncman expands on findings from a multicenter Polish study analyzing referral patterns and clinical practice in patients with unresectable stage III NSCLC, emphasizing that access to the modern standard of care depends on a chain of eligibility.
-
Opti-TROP Lung 05 Trial Results Expand First-Line Treatment Options for PD-L1-Positive Advanced NSCLC
Dr. Caicun Zhou indicated that treatment with sac-TMT plus pembrolizumab demonstrated a clinically meaningful PFS benefit and favorable OS trends compared with pembrolizumab monotherapy.